ArticleESC heart failure2021
The prognostic value of serial troponin measurements in patients admitted for COVID-19.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myocardial injury in hospitalized COVID-19 patients: a retrospective study, systematic review, and meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages.Journal of clinical immunology · 2025Article
- Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.ESC heart failure · 2025Review
- Surfactant-derived protein type B: a new biomarker linked to respiratory failure and lung damage in mild to moderate SARS-CoV-2 pneumonia.ERJ open research · 2024Article
- Comorbidities and mortality risk in COVID-19 patients with congestive heart failure: A comprehensive analysis.Heliyon · 2024Article
- Predictors and Clinical Significance of Myocardial Injury in Elderly Patients Under the COVID-19 Pandemic.International journal of general medicine · 2024Article
- Use and Prognostic Implications of Cardiac Troponin in COVID-19.Heart failure clinics · 2023Review
- Reshaping care in the aftermath of the pandemic. Implications for cardiology health systems.European journal of internal medicine · 2023Review
- COVID-19 and the heart.World journal of clinical cases · 2022Review
- Clinical characterization and natural history of chemotherapy-induced dilated cardiomyopathy.ESC heart failure · 2022Article
- Serial cardiac biomarkers for risk stratification of patients with COVID-19.Clinical biochemistry · 2022Article
- Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.European heart journal. Case reports · 2022Article
- Use and Prognostic Implications of Cardiac Troponin in COVID-19.Cardiology clinics · 2022Review
- Characteristic Immune Dynamics in COVID-19 Patients with Cardiac Dysfunction.Journal of clinical medicine · 2022Article
- Article
- Does Losartan reduce the severity of COVID-19 in hypertensive patients?BMC cardiovascular disorders · 2022Article
- Patients hospitalised with heart failure across different waves of the COVID-19 pandemic show consistent clinical characteristics and outcomes.International journal of cardiology · 2022Article
- Prognostic implications of serial high-sensitivity cardiac troponin testing among patients with COVID-19: A Danish nationwide registry-based cohort study.American heart journal plus : cardiology research and practice · 2022Article
- A year in heart failure: an update of recent findings.ESC heart failure · 2021Review
- The prognostic value of serial troponin measurements in patients admitted for COVID-19.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMyocardial injury (MI) in coronavirus disease-19 (COVID-19) is quite prevalent at admission and affects prognosis. Little is known about troponin trajectories and their prognostic role. We aimed to describe the early in-hospital evolution of MI and its prognostic impact. METHODS AND
resultsWe performed an analysis from an Italian multicentre study enrolling COVID-19 patients, hospitalized from 1 March to 9 April 2020. MI was defined as increased troponin level. The first troponin was tested within 24 h from admission, the second one between 24 and 48 h. Elevated troponin was defined as values above the 99th percentile of normal values. Patients were divided in four groups: normal, normal then elevated, elevated then normal, and elevated. The outcome was in-hospital death. The study population included 197 patients; 41% had normal troponin at both evaluations, 44% had elevated troponin at both assessments, 8% had normal then elevated troponin, and 7% had elevated then normal troponin. During hospitalization, 49 (25%) patients died. Patients with incident MI, with persistent MI, and with MI only at admission had a higher risk of death compared with those with normal troponin at both evaluations (P < 0.001). At multivariable analysis, patients with normal troponin at admission and MI injury on Day 2 had the highest mortality risk (hazard ratio 3.78, 95% confidence interval 1.10-13.09, P = 0.035).
conclusionsIn patients admitted for COVID-19, re-test MI on Day 2 provides a prognostic value. A non-negligible proportion of patients with incident MI on Day 2 is identified at high risk of death only by the second measurement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.